Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

Similar articles for PubMed (Select 11684959)

1.

Increased expression of tenascin in pheochromocytomas correlates with malignancy.

Salmenkivi K, Haglund C, Arola J, Heikkilä P.

Am J Surg Pathol. 2001 Nov;25(11):1419-23.

PMID:
11684959
2.

VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome.

Salmenkivi K, Heikkilä P, Liu J, Haglund C, Arola J.

APMIS. 2003 Apr;111(4):458-64.

PMID:
12780519
3.

Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.

Luo Z, Li J, Qin Y, Ma Y, Liang X, Xian J, Lu D, Wei M, Yang JY, Yang MQ, He Z.

Endocr Pathol. 2006 Winter;17(4):387-98.

PMID:
17525487
4.

Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.

Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA.

Surgery. 2008 Jun;143(6):759-68. doi: 10.1016/j.surg.2008.02.007. Epub 2008 Apr 14.

PMID:
18549892
5.

Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.

Kumaki N, Kajiwara H, Kameyama K, DeLellis RA, Asa SL, Osamura RY, Takami H.

Endocr Pathol. 2002 Summer;13(2):149-56.

PMID:
12165664
6.

Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.

Sadow PM, Rumilla KM, Erickson LA, Lloyd RV.

Endocr Pathol. 2008 Summer;19(2):97-103. doi: 10.1007/s12022-008-9028-0.

PMID:
18461287
7.

Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.

Salmenkivi K, Haglund C, Ristimäki A, Arola J, Heikkilä P.

J Clin Endocrinol Metab. 2001 Nov;86(11):5615-9.

PMID:
11701743
9.

Malignancy in pheochromocytomas.

Salmenkivi K, Heikkilä P, Haglund C, Arola J.

APMIS. 2004 Sep;112(9):551-9. Review.

PMID:
15601303
10.

Differential heparanase-1 expression in malignant and benign pheochromocytomas.

Quiros RM, Kim AW, Maxhimer J, Gattuso P, Xu X, Prinz RA.

J Surg Res. 2002 Nov;108(1):44-50.

PMID:
12443714
11.

[The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].

Feng C, Li HZ, Yan WG, Gao JG, Xu WF, Luo YF, Cao JL.

Zhonghua Wai Ke Za Zhi. 2007 Dec 15;45(24):1697-700. Chinese.

PMID:
18476530
12.
13.

Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.

Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G.

Endocr Relat Cancer. 2008 Mar;15(1):343-50. doi: 10.1677/ERC-07-0188.

14.

Survivin: a novel neuroendocrine marker for pheochromocytoma.

Koch CA, Vortmeyer AO, Diallo R, Poremba C, Giordano TJ, Sanders D, Bornstein SR, Chrousos GP, Pacak K.

Eur J Endocrinol. 2002 Mar;146(3):381-8.

15.

Stathmin as a marker for malignancy in pheochromocytomas.

Björklund P, Cupisti K, Fryknäs M, Isaksson A, Willenberg HS, Akerström G, Hellman P, Westin G.

Exp Clin Endocrinol Diabetes. 2010 Jan;118(1):27-30. doi: 10.1055/s-0029-1202789. Epub 2009 May 15.

PMID:
19449284
16.

[Pheochromocytoma--pathohistologic and immunohistochemical aspects].

Tatić S, Havelka M, Paunović I, Bozić V, Diklic A, Brasanac D, Janković R, Jancić-Zguricas M.

Srp Arh Celok Lek. 2002 Jul;130 Suppl 2:7-13. Serbian.

PMID:
12584991
17.

KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.

Elder EE, Xu D, Höög A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C, Bäckdahl M.

Mod Pathol. 2003 Mar;16(3):246-55.

18.

Differential diagnosis of pheochromocytomas and paragangliomas.

McNichol AM.

Endocr Pathol. 2001 Winter;12(4):407-15. Review.

PMID:
11914474
19.

[Distinction between benign and malignant pheochromocytomas].

Liu TH, Chen YJ, Wu SF, Gao J, Jiang WJ, Lu ZH, Guan J, Wei SZ, Luo YF, Cao JL, Wan JW.

Zhonghua Bing Li Xue Za Zhi. 2004 Jun;33(3):198-202. Chinese.

PMID:
15256107
20.

Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.

Tavangar SM, Shojaee A, Moradi Tabriz H, Haghpanah V, Larijani B, Heshmat R, Lashkari A, Azimi S.

Pathol Res Pract. 2010 May 15;206(5):305-9. doi: 10.1016/j.prp.2010.01.007. Epub 2010 Mar 1.

PMID:
20189725
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk